

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



KINGWORLD MEDICINES GROUP LIMITED
金活醫藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code : 01110)

INSIDE INFORMATION
UPDATE ON LITIGATION

This announcement is made by Kingworld Medicines Group Limited (the “**Company**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the paragraph headed “Litigation” in the 2015 Annual Report, the 2016 Annual Report, the 2017 Annual Report, the 2018 Annual Report, the 2019 Annual Report and the 2020 Annual Report of the Company, the paragraph headed “Contingent liabilities, legal and potential proceedings” in the 2016 Interim Report, the 2017 Interim Report, the 2018 Interim Report, the 2019 Interim Report, the 2020 Interim Report and the 2021 Interim Report of the Company, the announcement of the Company dated 24 October 2016 (the “**Announcement**”), the announcement of the Company dated 31 October 2016 (the “**Second Announcement**”), the announcement of the Company dated 10 August 2018 (the “**Third Announcement**”) and the announcement of the Company dated 2 August 2019 (the “**Fourth Announcement**”) in relation to update on litigation. Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Announcement, the Second Announcement, the Third Announcement and the Fourth Announcement.

The Company wishes to update its shareholders and potential investors that, based on the judgment (the “**2021 Judgment**”) recently handed down by the Intermediate Court, the Intermediate Court ruled to dismiss all claims of the plaintiff of the first instance that the Substantial Shareholder shall not be required to transfer his 15% equity interest in Dong Di Xin to the plaintiff of the first instance, and Dong Di Xin shall not be required to undertake relevant assistance obligations.

The Company confirms that the 2021 Judgment did not and will not have any material adverse impact on the ordinary operations and financial positions of the Company and its subsidiaries.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Kingworld Medicines Group Limited
Zhao Li Sheng
Chairman

Hong Kong, 17 January 2022

As at the date of this announcement, the executive Directors are Mr. Zhao Li Sheng, Ms. Chan Lok San and Mr. Zhou Xuhua, and the independent non-executive Directors are Mr. Duan Jidong, Mr. Zhang Jianbin and Mr. Wong Cheuk Lam.